Table 3. Reportable events and treatment adjustments.
| Dog ID Time of event | Placebo Group | Valspodar Group |
|---|---|---|
| MN06
Day 3 |
Inappetence (grade 1) |
|
| MN08
Day 2 |
Inappetence (grade 2) Lethargy (grade 2) |
|
| PD02
Day 1 1 |
Gastrointestinal 2 (grade 2) Lethargy (grade 1) |
|
| PD05
Day 1 after first dose of doxorubicin 3 |
Lethargy (grade 1) Gastrointestinal 4 (grade 2) Hematological 5 (grade 2) |
|
| PENN02
Day 2 and Day 5 Days 6–11 after first dose of doxorubicin |
Gastrointestinal 6 (grade 1) Inappetence (grade 3) Lethargy (grade 2) |
|
| PENN05
Day 4 Day 11 |
Bilateral scleral congestion Suspected hyphema OS (grade 2) Lymphadenopathy Uveitis OD (grade 2) |
1Owner elected to withdraw dog from study prior to receiving doxorubicin
2Vomiting and diarrhea
3Dog’s second doxorubicin treatment was dosed at 21 mg/m 2; similar toxic effects were not observed. However, the dog’s owner only permitted subsequent doxorubicin doses to be escalated to 24 mg/m 2
4Diarrhea
5Neutropenia (grade 2) and thrombocytopenia (grade 1)
6Vomiting